Relationship of hospital-associated bleeding with length of stay and total hospitalization costs in patients hospitalized for atrial fibrillation

被引:4
作者
Amin, Alpesh N. [1 ]
Robinson, Scott B. [2 ]
Bowdy, Bruce D. [2 ]
Jing, Yonghua [3 ]
Johnson, Bernadette H. [2 ]
Wiederkehr, Daniel P. [4 ]
机构
[1] Univ Calif Irvine, Irvine, CA 92868 USA
[2] Premier Res Serv, Charlotte, NC USA
[3] Abbvie, Chicago, IL USA
[4] Pfizer, New York, NY USA
关键词
Non-valvular atrial fibrillation; Hospital associated bleed; Length of stay; Total hospitalization cost; PERCUTANEOUS CORONARY INTERVENTION; ORAL ANTICOAGULATION; STROKE PREVENTION; RISK-FACTORS; WARFARIN; THERAPY; POPULATION; ASPIRIN; EVENTS; IMPACT;
D O I
10.3111/13696998.2015.1134545
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background:While literature has focused on the impact of bleeding beginning outside the hospital setting among patients with atrial fibrillation (AF), there is little information regarding bleeding that first occurs within a hospital setting. This study was performed to determine the association between hospital-associated bleeding in patients admitted for AF on outcomes of length of stay (LOS) and total hospitalization cost.Methods and results:The Premier research database was queried to identify adult inpatients discharged between 2008-2011 having a primary diagnosis code for AF where a bleeding diagnosis code was not present on admission. Regression was used to adjust for baseline differences in patients to estimate outcomes comparing patients with and without a hospital-associated bleed. There were 143,287 patients that met the study criteria. There were 2991 (2.1%) patients identified with a hospital associated bleed. After adjustment for covariates, the mean estimated LOS was significantly greater in the bleed group, at 6.0 days (95% CI=5.8-6.1) vs the no bleed group at 3.3 days (95% CI=3.3-3.3) (p<0.0001). Similarly, the adjusted mean estimated total hospitalization cost was also significantly greater in the bleed group, $12,069 (95% CI=$11,779-$12,366) vs $6561 (95% CI=$6538-$6583) in the no bleed group (p<0.0001).Conclusions:After adjustments for baseline differences the data show that the 2.1% (n=2991) of patients with hospital associated bleeding accounted for an estimated additional 8106 hospitalization days and $16.4 million dollars in cost over the study period compared to non-bleeders.
引用
收藏
页码:490 / 496
页数:7
相关论文
共 25 条
  • [11] Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score
    Lip, Gregory Y. H.
    Frison, Lars
    Halperin, Jonathan L.
    Lane, Deirdre A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (02) : 173 - 180
  • [12] Lifetime risk for development of atrial fibrillation - The Framingham Heart Study
    Lloyd-Jones, DM
    Wang, TJ
    Leip, EP
    Larson, MG
    Levy, D
    Vasan, RS
    D'Agostino, RB
    Massaro, JM
    Beiser, A
    Wolf, PA
    Benjamin, EJ
    [J]. CIRCULATION, 2004, 110 (09) : 1042 - 1046
  • [13] Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
    Mant, Jonathan
    Hobbs, F. D. Richard
    Fletcher, Kate
    Roalfe, Andrea
    Fitzmaurice, David
    Lip, Gregory Y. H.
    Murray, Ellen
    [J]. LANCET, 2007, 370 (9586) : 493 - 503
  • [14] Bleeding in Patients Undergoing Percutaneous Coronary Intervention The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry
    Mehta, Sameer K.
    Frutkin, Andrew D.
    Lindsey, Jason B.
    House, John A.
    Spertus, John A.
    Rao, Sunil V.
    Ou, Fang-Shu
    Roe, Matthew T.
    Peterson, Eric D.
    Marso, Steven P.
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (03) : 222 - U107
  • [15] Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study
    Nieuwlaat, Robby
    Connolly, Benjamin J.
    Hubers, Lowiek M.
    Cuddy, Spencer M.
    Eikelboom, John W.
    Yusuf, Salim
    Connolly, Stuart J.
    [J]. THROMBOSIS RESEARCH, 2012, 129 (06) : 715 - 719
  • [16] Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years
    Poli, Daniela
    Antonucci, Emilia
    Grifoni, Elisa
    Abbate, Rosanna
    Gensini, Gian Franco
    Prisco, Domenico
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (11) : 999 - 1002
  • [17] Psaty BM, 1997, CIRCULATION, V96, P2455
  • [18] Rao SV, 2010, REV ESP CARDIOL, V63, P1
  • [19] Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?
    Ruiz-Nodar, Juan M.
    Marin, Francisco
    Roldan, Vanessa
    Valencia, Jose
    Manzano-Fernandez, Sergio
    Caballero, Luis
    Hurtado, Jose A.
    Sogorb, Francisco
    Valdes, Mariano
    Lip, Gregory Y. H.
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (04) : 459 - 466
  • [20] Steiner C, 2012, 201202 HCUP US AG HE